NCT04508907

A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients

Pilot Study for the Use of Shortened Preemptive Therapy With Glecaprevir/Pibrentasvir (G/P) and Ezetimibe in Hepatitis C Seronegative Solid Organ Transplant Recipients (Kidney, Heart, Lung and/or Pancreas) of Hepatitis C Viremic Donors

• Status: Active Not Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.

Conditions

• Hepatitis C
• Kidney Transplant; Complications
• Heart Transplant Infection

Interventions

Type	Name	Description
DRUG	Mavyret	Mavyret and Zetia for 8 days to prevent HCV infection in solid organ recipients

Timeline

• Start date: 2020-09-10
• Primary completion: 2025-11-01
• Completion: 2026-11-01
• First posted: 2020-08-11
• Last updated: 2025-12-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study